Kips Pharma's Q3 Cumulative Revenue Hits KRW 202.8 Billion, Surpassing Full-Year Revenue in Nine Months
Kips Biopharma (hereinafter, Kips Pharma) recorded cumulative revenue of KRW 202.8 billion through the third quarter of this year, surpassing its full-year revenue for last year in just nine months. Growth in its pharmaceutical and biotech business and the effects of a series of mergers and acquisitions (M&A) drove its expansion. However, operating losses continued due to the burden of research and development (R&D) investment and costs associated with business expansion.
According to the Financial Supervisory Service’s electronic disclosure system on November 16, Kips Pharma’s cumulative consolidated revenue through the third quarter was KRW 202.8 billion, up 62% from KRW 124.9 billion in the same period last year. It also surpassed last year’s full-year revenue of KRW 170.1 billion in just nine months. Third-quarter revenue was KRW 68.4 billion, up 67% from KRW 40.9 billion in the same period last year. Quarterly revenue growth remained strong, at 46% in the first quarter, 73% in the second quarter, and 67% in the third quarter.
The pharmaceutical and biotech segment led the growth. Its cumulative revenue through the third quarter was KRW 69.3 billion, up 92% from KRW 36.2 billion in the same period last year. It had already surpassed its full-year revenue of KRW 49.2 billion last year. Standalone third-quarter revenue reached a quarterly record of KRW 27.4 billion, up 127% from KRW 12.1 billion in the same period last year. The segment’s share of total revenue also rose by 10 percentage points, from 30% to 40%.
The company said it had expanded its pharmaceutical and biotech business by securing new products and clients and pursuing M&A. Bigthink, its subsidiary specializing in anticancer drugs, recorded cumulative revenue of KRW 9.6 billion through the third quarter, nearly three times the KRW 3.3 billion posted in the same period last year. Its cumulative operating profit also turned positive at KRW 300 million.
Elpis Pharm, a distributor specializing in anticancer drugs acquired this year, also contributed to growth. Consolidated in the company’s results starting in the second quarter, Elpis Pharm recorded cumulative revenue of KRW 23.5 billion and operating profit of KRW 700 million through the third quarter.
While revenue growth continued, improving profitability remained a challenge. Kips Pharma posted a cumulative consolidated operating loss of KRW 8 billion and a net loss of KRW 8.6 billion through the third quarter. The company said these results reflected costs incurred in developing key pipeline products and expanding its business. It expects profitability to improve as the benefits of its expanded scale begin to materialize.
Kim Hayong, CEO of Kips Pharma, said, "We surpassed last year’s full-year revenue in just nine months, driven by the expansion of our pharmaceutical and biotech business and the effects of M&A. Going forward, we will focus on securing profitability commensurate with our growth."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, "The development of new drugs is proceeding as planned. Starting in the first half of 2027, we expect to announce concrete achievements, including interim results from the UK combination trial of idetrexed, a next-generation ovarian cancer treatment, and additional patents for Oraloyd, our oral platform."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.